MitoQ for Fatigue in Multiple Sclerosis
MitoQ for Fatigue in Multiple Sclerosis: a Placebo Controlled Trial
What it found
The trial ended early for another reason (see below).
Reason given: Lack of adequate funding
This trial finished 7 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Mitoquinone cation
Placebo
- Placebo
What it measured
Main measures
Fatigue measured by Modified Fatigue Impact Scale (MFIS) Score at 12 weeks post study drug initiation
Baseline to 12 weeks post drug initiation.
Fatigue
Who could take part
MS (type not specified) · 18 to 70 · EDSS 2 to 8
Show the full criteria
Inclusion criteria
* MS (any clinical subtype) as diagnosed by the 2010 McDonald criteria40; * Expanded Disability Status Scale (EDSS) score of 2 to 8, * Complaint of fatigue that has been persistent for at least two months; * Modified Fatigue Impact Scale (MFIS) score of 38 or greater
Exclusion criteria
* Treatment with systemic glucocorticoids in the prior six weeks; * Beck Depression Inventory (BDI) >31 (severe depression); * Significant MS exacerbation in prior 30 days; * Previous use of MitoQ or CoQ-10 within 30 days of screening appointment; * Use of non-research-pharmacy-administered MitoQ or CoQ-10 during the duration of the study; * Other significant health problem (e.g. active coronary heart disease, liver disease, pulmonary disease, diabetes mellitus) that might increase risk of patient experiencing adverse events), * Pregnancy or intending to become pregnant or breastfeeding; * Unable to complete the self-report forms; * Unable to give informed consent; * Prisoners will be excluded. * Any condition which would make the patient, in the opinion of the investigator, unsuitable for the study.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after study drug initiation will assess if MitoQ has a significant change in fatigue.
Papers
Loading reviews and guidelines…
History
Started
Sept 2018
Main results due
Jan 2019
Finished
Jan 2019